	US 11,813,233 B2
	Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
Claus Rieker, St-Sulpice (CH); Julie Hudry-Labbe, Epalinges (CH); Jeroen Antonius Johannes Schmitt, Moudon (CH); Corina Boschat, Lausanne (CH); and Yvonne Beata Silber, Essertes (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 16/336,294
Filed by NESTEC S.A., Vevey (CH)
PCT Filed Sep. 29, 2017, PCT No. PCT/EP2017/074731 § 371(c)(1), (2) Date Mar. 25, 2019, PCT Pub. No. WO2018/060396, PCT Pub. Date Apr. 5, 2018.
Claims priority of provisional application 62/401,443, filed on Sep. 29, 2016.
Claims priority of provisional application 62/484,119, filed on Apr. 11, 2017.
Claims priority of provisional application 62/484,156, filed on Apr. 11, 2017.
Prior Publication US 2020/0046660 A1, Feb. 13, 2020
Int. Cl. A61K 31/202 (2006.01); A61K 31/197 (2006.01); A61K 31/519 (2006.01); A61K 31/14 (2006.01); A61K 31/714 (2006.01); A61K 31/198 (2006.01); A61K 31/4415 (2006.01); A61K 31/17 (2006.01); A61K 31/375 (2006.01); A61K 31/4406 (2006.01); A61K 33/00 (2006.01); A61K 31/341 (2006.01); A61K 31/355 (2006.01); A61K 31/4188 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/525 (2006.01); A61K 31/59 (2006.01); A61K 31/675 (2006.01); A61K 33/04 (2006.01)

CPC A61K 31/714 (2013.01) [A61K 31/14 (2013.01); A61K 31/17 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 31/341 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4188 (2013.01); A61K 31/4406 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/519 (2013.01); A61K 31/525 (2013.01); A61K 31/59 (2013.01); A61K 31/675 (2013.01); A61K 33/00 (2013.01); A61K 33/04 (2013.01)]

11 Claims

1. A method of achieving a benefit selected from the group consisting of decreasing brain atrophy, increasing or maintaining number of synapses, and combinations thereof, in a non-demented individual in need thereof, the method comprising administering to the non-demented individual a therapeutically effective amount of a composition comprising an omega-3 fatty acid, choline, and a B vitamin, the composition is administered to the individual in a daily dose that provides 85 mg of choline per day, 770 mg of docosahexaenoic acid (DHA) per day, 770 mg of eicosapentaenoic acid (EPA) per day, and 0.03 mg to 0.05 mg of Vitamin B12 per day, the non-demented individual is an older adult and has an erythrocyte omega 3 index<4.8% at baseline.